-- Announced FDA acceptance for review of the Peg-IFN (peginterferon alfa-
2b) supplemental Biologics License Application, granted Priority Review
status for the adjuvant treatment of patients with Stage III melanoma.
(Announced Jan. 31, 2008)
-- Reported that the antifungal agent NOXAFIL (posaconazole) Oral
Suspension had received an A-1 recommendation (highest rating) for the
prevention of invasive Aspergillus infections in certain high-risk
patients in the latest Treatment of Aspergillosis Clinical Practice
Guidelines of the Infectious Diseases Society of America. (Announced
Jan. 31, 2008)
-- Gained FDA approval of ASMANEX TWISTHALER (mometasone furoate
inhalation powder) for the maintenance treatment of asthma as a
preventive therapy in patients 4 to 11 years of age. (Announced Feb.
-- Announced final results of a Phase II clinical study showing that
vicriviroc, an investigational CCR5 antagonist, demonstrated potent and
sustained viral suppression through 48 weeks of therapy in treatment-
experienced HIV-infected patients, when administered once-daily as a
single tablet in combination with an optimized ritonavir-boosted
protease inhibitor-containing antiretroviral regimen. (Announced Feb.
Fourth Quarter 2007 Conference Call and Webcast
Schering-Plough will conduct a conference call today at 8 a.m. (EST) to
review the 2007 fourth quarter and full-year results. To listen live to the
call, dial 1-877-565-9664 or 1-706-634-5003 and enter conference ID
#26183610. A replay of the call will be available beginning later today
through 5 p.m. on March 11. To listen to the replay, dial 1-800-642-1687 or
1-706-645-9291 and enter the conference ID #26183610. A live audio webcast
of the conference call also will be availab
|SOURCE Schering-Plough Corporation|
Copyright©2008 PR Newswire.
All rights reserved